Women's perspective of botulinum toxin treatment for overactive bladder symptoms

International Urogynecology Journal

Volumn 22, Issue 4, 2011, Pages 425-431

  Digesu, G Alessandro ^a   Panayi, Demetri ^a   Hendricken, Caroline ^a   Camarata, Michelle ^a   Fernando, Ruwan ^a   Khullar, Vikram ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Boxstulinum toxin; Complications; Expectation; Overactive bladder; Perspective of outcome; Women

Indexed keywords

BOTULINUM TOXIN; ANTIPARKINSON AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVERACTIVE BLADDER; PATIENT ASSESSMENT; PATIENT ATTITUDE; PATIENT COUNSELING; PRIORITY JOURNAL; QUESTIONNAIRE; MIDDLE AGED; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; STATISTICS;

ADULT; AGED; ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; FEMALE; HUMANS; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PROSPECTIVE STUDIES; URINARY BLADDER, OVERACTIVE;

EID: 79959794286     PISSN: 09373462     EISSN: 14333023     Source Type: Journal    
DOI: 10.1007/s00192-010-1315-x     Document Type: Article

References (26)

1. Abrams P, Cardozo L, Fall M et al (2002) The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol Urodyn 21:167-178 (Pubitemid 34195211)
2. Stewart WF, Van Rooyen JB, Cundiff GW et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327-336 (Pubitemid 44175300)
3. Abrams P (2000) Introduction: overactive bladder and its treatments. Urology 55:1-2
4. Stewart WF, Corey R, Herzog AR et al (2001) Prevalence of overactive bladder in women: results from the NOBLE program. Int Urogynaecol J 12:S66
5. Srikrishna S, Robinson D, Cardozo L, Vella M (2007) Management of overactive bladder syndrome. Postgrad Med J 83(981):481-486 (Pubitemid 47123321)
6. Andersson K-E (1988) Current concepts in the treatment of disorders of micturition. Drugs 35:477-494
7. Payne CK, Kelleher C (2007) Redefining response in overactive bladder syndrome. BJU Int 99(1):101-106 (Pubitemid 44915628)
8. Salvatore S, Khullar V, Cardozo L et al (2005) Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity. Eur J Obstet Gynecol Reprod Biol 119:237-241 (Pubitemid 40460389)
9. Kelleher CJ, Cardozo LD, Khullar V et al (1997) A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 104:988-993 (Pubitemid 27400176)
10. Rapp DE, Lucioni A, Katz EE et al (2004) Use of botulinum toxin A for the treatment of refractory overactive bladder symtptoms: an initial experience. Urolog 63:1071-1075 (Pubitemid 38746805)
11. Kuo HC (2004) Urodynamic evidence of effectiveness of botulinum A toxin injection in the treatment of detrusor overactivity refractory to anticholinergic agents. Urology 63:868-872
12. Chancellor MB, O'Leary M, Erickson J (2003) Successful use of bladder botulinum toxin injection to treat refractory overactive bladder. J Urol 169(suppl):351
13. Abrams P, Andersson KE, Birder L et al (2009) Proceedings of the 4th International consultation on incontinence. Recommendations of the international scientific committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence. In: Abrams P, Cardozo L, Khouri S, Wein A (eds) Incontinence. Plymouth, UK, pp 1767-1798
14. Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164:692-697 (Pubitemid 30637604)
15. Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB (2004) Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology 64:871-875 (Pubitemid 39469494)
16. Apostolidis A, Popat R, Yiangou Y et al (2005) Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 174:977-982 (Pubitemid 41140654)
17. Schmid DM, Sauermann P, Werner M et al (2006) Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 176(1):177-185 (Pubitemid 43815416)
18. Patel AK, Patterson JM, Chapple CR (2006) Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: a critical analysis of results. Eur Urol 50:684-709
19. Sahai A, Dowson C, Khan MS, Dasgupta P (2008) Re: efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int 101(4):515-516 (Pubitemid 351160943)
20. Jeffery S, Fynes M, Lee F, Wang K, Williams L, Morley R (2007) Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int 100(6):1302-1306 (Pubitemid 350043916)
21. Kuo HC (2007) Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol 178:1359-1363
22. Mattiasson A, Djurhuus JC, Fonda D, Lose G, Nordling J, Stohrer M (1998) Standardisation of outcome studies in patients with lower urinary tract dysfunction: a report on general principles from the standardisation committee of the International Continence Society. Neurourol Urodyn 17:249-253 (Pubitemid 28201709)
23. Blaivis JG, Appell RA, Fantl JA et al (1997) Standards of efficacy for evaluation of treatment outcomes in urinary incontinence: recommendations of the urodynamic society. Neurourol Urodyn 16:145-147 (Pubitemid 27190989)
24. Blaivas JG (1998) Outcome measures for urinary incontinence. Urology 51:11-19 (Pubitemid 28128542)
25. Scientific Committee of the First Consultation on Incontinence (2000) Assessment and treatment of urinary incontinence. Lancet 355:2153-2158
26. Apostolidis A, Dasgupta P, Denys P et al (2009) Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 55(1):100-119